{"name":"iOMEDICO AG","slug":"iomedico-ag","ticker":"","exchange":"","domain":"iomedico.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Calquence","genericName":"Calquence","slug":"calquence","indication":"Chronic lymphocyticleukemia/small lymphocytic lymphoma","status":"marketed"}]}],"pipeline":[{"name":"Calquence","genericName":"Calquence","slug":"calquence","phase":"marketed","mechanism":"Platelet glycoprotein VI, Cytoplasmic tyrosine-protein kinase BMX, Tyrosine-protein kinase Blk","indications":["Chronic lymphocyticleukemia/small lymphocytic lymphoma","Mantle cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOdHRkY0VlUGM4UE4ydjV1UlZUS0pnWEkteUN1WGg5bV9YMVUyckp1N3R3SlcyMEh6QVJJSGFxQTB1aVdUVXpmcVlsZEQtOVRLQ0xkT19lczhoa2QwaV9BQkppa3UyOUR0VlRPaFREQUhXSnpPRDBsd2lLSV9UV0lRd21Hb09sQ3hFZlE4bmhrMkRtQnZvR0xuSEx5YXRZbHNPQmFzN2JkSWVtaHp1QzFJTXV6UVdSWkNGYkd3NnZ2bW1oc0d3Z09ZSVVlOVIxcHVua2xxcTZn?oc=5","date":"2024-03-06","type":"trial","source":"BioSpace","summary":"PhaseV and iOMEDICO Partner to Launch New ML-Powered Solution to Increase Success Rates of Phase 3 Oncology Trials - BioSpace","headline":"PhaseV and iOMEDICO Partner to Launch New ML-Powered Solution to Increase Success Rates of Phase 3 Oncology Trials","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}